15th Annual Scientific Meeting Posters

Poster PDFs and abstracts are in alphabetical order by author.

Clinical trial design considerations for novel therapies in patients showing inadequate response (Abstract)

Alphs

Trials errors and placebo prediction: Tradeoffs between effect size and sample size in machine learning models (Abstract)

Anderson

Assessing decline in visuospatial working memory associated with subjective cognitive impairment (Abstract)

Atkins

Experimental pain evaluation in Japanese healthy volunteers using the cold pressor test (Abstract)

Chung

Taming the placebo effect in depression clinical trials: Implementation of a placebo-control reminder script (Abstract)

Cohen

The New York assessment of adverse cognitive effects of neuropsychiatric treatment NY-AACENT (Abstract)

Correll

Implementation of a fully virtual trial in an interventional study of caffeine effects (Abstract)

Curtin

Comparison of PANSS logical error rates using eCOA vs paper data collection (Abstract)

Daniel

Efficient use of baseline can increase power and reduce bias in psychiatric crossover trials (Abstract)

Farmer

Outlier safety data with esketamine nasal spray plus oral antidepressant in SUSTAIN-2 (Abstract)

Fua

Machine learning approach to predict diagnostic category change in pre-dementia (Abstract)

Gill

The kynurenine pathway and bipolar disorder intersection of monoaminergic and glutamatergic systems (Abstract)

Kadriu

Quantitative disease-drug-trial models for effectiveness in adolescent schizophrenia trials (Abstract)

Kalaria

Activity monitoring in Alzheimer disease and irregular sleep-wake-rhythm disorder (Abstract)

Kemethofer

Assessing the eCOA user experience for evaluating virtual functional outcomes (Abstract)

Khan

Exploring association of PANSS rater change with within-subject variability (Abstract)

Kott

Procedural and methodological issues implementing digital health programs in schizophrenia (Abstract)

Lindenmayer

Risks to signal detection in phase 3 schizophrenia trials (Abstract)

McNamara

Comparisons of symptom severity by independent vs site-based raters in MDD trial (Abstract)

Nash

Neurophysiological effects of intravenous alcohol as biomarkers of ketamine response (Abstract)

Niciu

Impact of innovative trial designs on CNS drug development (Abstract)

Olugemo

Investigating placebo effects in Alzheimer disease agitation trial (Abstract)

Ruthirakuhan

Subject variability from phase 2 to phase 3 clinical trials (Abstract)

Shiovitz

Verbatim reports from over 10000 Parkinson disease patients (Abstract)

Shoulson

Impact of midazolam versus saline on effect size in ketamine trials (Abstract)

Wilkinson

Linking adverse events of dissociation with esketamine dosing severity (Abstract)

Williamson

CSF sampling by lumbar puncture in healthy Japanese elderly subjects (Abstract)

Yoshihara

Efficient methods for COA instrument selection in Alzheimer disease trials (Abstract)

Zaragoza-Domingo

Identification of neurorestorative biomarkers in multiple sclerosis (Abstract)

Ziemann